There's no clear cut answer to that. I would expect that the first 65 patients or so were placebo only. They should break out that portion of the study but the small patient population it could fall either way and would have a very broad confidence interval.

For the entire study it will be determined by how many patients were given treatments that were somewhat effective. They might have helped stave off death for at least 28 days even if those patients still remained on vents. Then there's the problem of immunosuppressants like IL-6 inhibitors being used in the leronlimab arm. Not only would leronlimab have to counteract the suppressive ability of the virus itself but the immunosuppression of the other drug. Then of course there's the question of which drug in the leronlimab arm actually did the heavy lifting.

If the FDA wants to give you a present make sure it's not boobytrapped with explosives.